Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy

References

• Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am. 1996;10(3):571–81.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Notes from the field: severe varicella in an immunocompromised child exposed to an unvaccinated sibling with varicella-Minnesota, 2011. MMWR. 2012;61(28):541.
   PubMedGoogle Scholar
• Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.
   PubMed Web of Science ®Google Scholar
• Yokota S. Juvenile rheumatoid arthritis (in Japanese). Nihon Rinsho. 2005;63:274–80.
   PubMedGoogle Scholar
• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42(4):712–22.
   PubMed Web of Science ®Google Scholar
• Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(8):2773–80.
   PubMed Web of Science ®Google Scholar
• Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, et al. Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(5):1384–9.
   PubMed Web of Science ®Google Scholar
• Kerensky TA, Gottlieb AB, Yaniv S, Au SC. Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf. 2012;11(1):121–39.
   PubMed Web of Science ®Google Scholar
• Bracaglia C, Buonuomo PS, Tozzi AE, Pardeo M, Nicolai R, Campana A, et al. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J Rheumatol. 2012;39(6):1287–90.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58(2):287–94.
   PubMed Web of Science ®Google Scholar
• Wiegering V, Schick J, Beer M, Weissbrich B, Gattenlöhner S, Girschick HJ, et al. Varicella-zoster virus infections in immunocompromised patients – a single centre 6-years analysis. BMC Pediatr. 2011;11:31. doi:10.1186/1471-2431-11-31.
   PubMed Web of Science ®Google Scholar
• Silk HJ, Guay-Woodford L, Perez-Atayde AR, Geha RS, Broff MD. Fatal varicella in steroid-dependent asthma. J Allergy Clin Immunol. 1988;81(1):47–51.
   PubMed Web of Science ®Google Scholar
• Hirose I, Ymamaguchi H, Inaguma D, Ono K, Shimada S, Kawada J, et al. Fatal varicella infection in a girl with systemic lupus erythematosus after oral acyclovir prophylaxis. Eur J Pediatr. 2006;165(4):280–1.
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol. 2010;25(11):1732–8.
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70(4):616–23.
   PubMed Web of Science ®Google Scholar
• García-Doval I, Pérez-Zafrilla B, Descalzo MA, Roselló R, Hernández MV, Gómez-Reino JJ. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis. 2010;69(10):1751–5.
   PubMed Web of Science ®Google Scholar
• Balato N, Gaudiello F, Balato A, Ayala F. Development of primary varicella infection during infliximab treatment for psoriasis. J Am Acad Dermatol. 2009;60(4):709–10.
   PubMed Web of Science ®Google Scholar
• Vonkeman H, ten Napel C, Rasker H, van de Laar M. Disseminated primary varicella infection during infliximab treatment. J Rheumatol. 2004;31(12):2517–18.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow up of 417 patients in Japan. Ann Rheum Dis. 2016;75:1654–60.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–95.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998–1006.
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol. 2009;19(1):64–8.
   PubMed Web of Science ®Google Scholar
• Hao M, Wang X, Du J, Liu L, Jiao Y, Wu H, et al. Cytokine levels are associated with the severity of varicella infections. J Infect Dev Ctries. 2015;9(2):190–6.
   PubMed Web of Science ®Google Scholar
• Wang JP, Kurt-Jones EA, Shin OS, Manchak MD, Levin MJ, Finberg RW. Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. J Virol. 2005;79(20):12658–66.
   PubMed Web of Science ®Google Scholar
• Choi EJ, Lee CH, Shin OS. Suppressor of cytokine signaling 3 expression induced by varicella-zoster virus infection results in the modulation of virus replication. Scand J Immunol. 2015;82(4):337–44.
   PubMed Web of Science ®Google Scholar
• Yokota S, Kikuchi M, Nozawa T, Kanetaka T, Sato T, Yamazaki K, et al. Pathogenesis of systemic inflammatory diseases in childhood: “Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome”. Mod Rheumatol. 2015;25(1):1–10.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford). 2010;49(9):1645–53.
   PubMed Web of Science ®Google Scholar
• Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4(6):387–97.
   PubMedGoogle Scholar
• Ozaki T, Nishimura N, Kajita Y. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic. Vaccine. 2000;18(22):2375–80.
   PubMed Web of Science ®Google Scholar
• Toplak N, Avčin T. Long-term safety and efficacy of varicella vaccination in children with juvenile idiopathic arthritis treated with biologic therapy. Vaccine. 2015;33(33):4056–9.
   PubMed Web of Science ®Google Scholar